FORA Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

FORA Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,708	Closed	-$378K	–	609
2023 Q2	$378K	Buy	+3,708	New	+$351K	0.05%	262
2020 Q1	–	Sell	-2,473	Closed	-$506K	–	1417
2019 Q4	$506K	Buy	+2,473	New	+$451K	0.05%	393

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FORA Capital's RETA Position: Q3 2023 in Review

FORA Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,708 shares — an estimated $378K sold.

FORA Capital first reported a position in RETA in Q4 2019 and held it in 2 quarters. The position peaked at $506K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

FORA Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
FORA Capital sold 3,708 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $378K.
FORA Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 2 quarters.
FORA Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $506K in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on FORA Capital's 13F filing for Q3 2023, filed 13 Nov 2023.